Wegovy pill: FDA greenlights 1st oral weight loss med for heart health
The FDA just approved Novo Nordisk's Wegovy pill—the first oral GLP-1 drug for chronic weight management and for reducing heart risks in adults with obesity or overweight.
The once-daily tablet will be available in the US starting January 2026.
How does it work, and what can you expect?
In trials, people taking the highest 25mg dose lost about 14% of their body weight—pretty much matching the results of the injectable version.
Doses start at 1.5mg and go up to 25mg, taken on an empty stomach each morning (and yes, you'll need to wait 30 minutes before breakfast).
Price tag and what's next
The lowest dose starts at $149/month; higher-dose pricing is still under wraps.
With about one in eight US adults already using meds like Wegovy or Zepbound, competition is heating up—especially since Eli Lilly's own weight loss pill is expected to be cleared by the FDA by summer 2026.